% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:890281,
      author       = {Galldiks, Norbert and Abdulla, Diana SY and Scheffler,
                      Matthias and Wolpert, Fabian and Werner, Jan-Michael and
                      Huellner, Martin W and Stoffels, Gabriele and Schweinsberg,
                      Viola and Schlaak, Max and Kreuzberg, Nicole and Landsberg,
                      Jennifer and Lohmann, Philipp and Ceccon, Garry and Baues,
                      Christian and Trommer, Maike and Celik, Eren and Ruge,
                      Maximilian I and Kocher, Martin and Marnitz, Simone and
                      Fink, Gereon R and Tonn, Joerg-Christian and Weller, Michael
                      and Langen, Karl-Josef and Wolf, Jürgen and Mauch,
                      Cornelia},
      title        = {{T}reatment {M}onitoring of {I}mmunotherapy and {T}argeted
                      {T}herapy using 18 {F}-{FET} {PET} in {P}atients with
                      {M}elanoma and {L}ung {C}ancer {B}rain {M}etastases:
                      {I}nitial {E}xperiences},
      journal      = {Journal of nuclear medicine},
      volume       = {62},
      number       = {4},
      issn         = {2159-662X},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {FZJ-2021-00862},
      pages        = {464-470},
      year         = {2021},
      abstract     = {We investigated the value of
                      O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for treatment
                      monitoring of immune checkpoint inhibition (ICI) or targeted
                      therapy (TT) alone or in combination with radiotherapy in
                      patients with brain metastasis (BM) since contrast-enhanced
                      MRI often remains inconclusive. Methods: We retrospectively
                      identified 40 patients with 107 BMs secondary to melanoma (n
                      = 29 with 75 BMs) or non–small cell lung cancer (n = 11
                      with 32 BMs) treated with ICI or TT who had 18F-FET PET (n =
                      60 scans) for treatment monitoring from 2015 to 2019. Most
                      patients (n = 37; $92.5\%)$ had radiotherapy during the
                      course of the disease. In 27 patients, 18F-FET PET was used
                      to differentiate treatment-related changes from BM relapse
                      after ICI or TT. In 13 patients, 18F-FET PET was performed
                      for response assessment to ICI or TT using baseline and
                      follow-up scans (median time between scans, 4.2 mo). In all
                      lesions, static and dynamic 18F-FET PET parameters were
                      obtained (i.e., mean tumor-to-brain ratios [TBR],
                      time-to-peak values). Diagnostic accuracies of PET
                      parameters were evaluated by
                      receiver-operating-characteristic analyses using the
                      clinical follow-up or neuropathologic findings as a
                      reference. Results: A TBR threshold of 1.95 differentiated
                      BM relapse from treatment-related changes with an accuracy
                      of $85\%$ (P = 0.003). Metabolic responders to ICI or TT on
                      18F-FET PET had a significantly longer stable follow-up
                      (threshold of TBR reduction relative to baseline, $≥10\%;$
                      accuracy, $82\%;$ P = 0.004). Furthermore, at follow-up,
                      time to peak in metabolic responders increased significantly
                      (P = 0.019). Conclusion: 18F-FET PET may add valuable
                      information for treatment monitoring in BM patients treated
                      with ICI or TT.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {32887757},
      UT           = {WOS:000658416500008},
      doi          = {10.2967/jnumed.120.248278},
      url          = {https://juser.fz-juelich.de/record/890281},
}